Medical marijuana contains compounds such as THC and CBD, known for their analgesic and anti-inflammatory properties. A study published in Pancreas journal found that cannabinoid receptors are present in the pancreas, indicating that cannabinoids may modulate pancreatic inflammation and pain signaling pathways.
Furthermore, a 2014 clinical review published in Clinical Gastroenterology and Hepatology noted the potential role of cannabinoids in managing chronic pain, including visceral pain like that associated with pancreatitis. The review emphasized the need for more targeted research, but acknowledged positive early results.
Patient-reported outcomes also support marijuana use. In a 2016 survey published in The Journal of Pain, medical cannabis users reported a 64% decrease in opioid use and improved quality of life in chronic pain conditions. While this study was not specific to pancreatitis, the overlap in chronic pain mechanisms suggests marijuana may benefit pancreatitis patients similarly.
Despite these findings, marijuana remains underutilized in pancreatitis treatment due to federal restrictions and limited clinical trials. As legislation evolves, further research is essential to validate and standardize marijuana’s therapeutic role in managing Chronic Pancreatitis.
References:
Michalski, C.W., et al. (2007). Cannabinoids in Pancreatic Diseases. Pancreas.
Farrell, L.J., et al. (2014). Pain Management in Chronic Pancreatitis. Clinical Gastroenterology and Hepatology.
Boehnke, K.F., et al. (2016). Medical Cannabis Use Is Associated With Decreased Opiate Medication Use. The Journal of Pain.
Dabbin-Dad Newsroom
If you liked this post, say thanks by sharing it
